The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small ...

Michelle C. Werner agonized over whether the gene therapy treatment Elevidys was right for her teenage son. But to him, the ...

A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.

Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...

While Dyne Therapeutics Inc.’s DYNE-251 demonstrated high levels of dystrophin expression and functional improvement in boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping, ...

Review highlights the growing evidence that aging is linked to reduced expression of long genes, offering insights into ...

The company announced that some of its senior executives have stepped down from their respective positions. Earlier, DYN reported mixed data from its ongoing phase I/II study, the DELIVER trial of ...

The boy who inspired "Michael's Cause" at age 4 is now a young adult whose family continues to fight for research of Duchenne Muscular Dystrophy.

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

Dyne (DYN) stock fell 31% after the company announced data for its drug DYNE-251 in the treatment of Duchenne muscular ...

Patients treated with 20 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin expression of 3.71% of normal. Dyne is initiating registrational cohorts in the DELIVER trial and plans to provide an ...

Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...